Table 2.

Clinical course and adverse events during 2-Year Follow-Up in IPF patients stratified by PH severity

	All	Severe PH	Less severe PH	ERPE	P-value for comparing event occurrence rates Severe vs Less severe PH Less severe PH vs ERPE Severe PH vs ERPE (P-value for comparing time to event occurrence)
Hospitalization resulting in lifelong inability to live at home (Home-stay survival days for those with hospitalization-event occurrence only)	21  (320.48± 245.07)	3 (335.00±279.85)	11 (377.09±253.49)	7 (225.29±224.59)	0.60 (0.64) 0.14 (0.16) 0.12 (0.73)
Death (Survival days for those with death-event occurrence only)	16 (381.94± 235.64)	3 (346.33± 292.34)	7 (437.57±236.63)	6 (334.83± 239.68)	0.27 (0.57) 0.74 (0.43) 0.047* (0.80)
Other	7 (Cerebral infarction: 1 Fracture due to fall: 1 Hepatitis:1 Pneumonia: 2 Myocardial infarction: 1 Depression: 1)	0	2 (Cerebral infarction: 1 Depression: 1)	5 (Fracture due to fall: 1 Hepatitis:1 Pneumonia: 2 Myocardial infarction: 1)	N.A

Data presented as mean ± SD

Values indicate number of events unless otherwise noted

PH Pulmonary hypertension, IPF Idiopathic pulmonary fibrosis, ERPE Exercise-Responsive PAP Elevation, ADL Activities of daily living

*P value for Wilcoxon signed-rank test to assess the difference between two groups in all possible group combinations